DAX24.340 +0,2%Est505.746 -0,1%MSCI World4.343 -0,1%Top 10 Crypto11,34 +2,5%Nas23.593 -0,1%Bitcoin76.452 +2,5%Euro1,1756 -0,1%Öl61,29 +0,8%Gold4.509 -0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Nike 866993 Novo Nordisk A3EU6F Rheinmetall 703000 DroneShield A2DMAA Allianz 840400 Deutsche Telekom 555750 BASF BASF11 Lufthansa 823212 Bayer BAY001 Amazon 906866 Tesla A1CX3T BYD A0M4W9 Alphabet A (ex Google) A14Y6F D-Wave Quantum A3DSV9
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt vor Weihnachten etwas höher -- Alphabet kauft Intersect -- Novo Nordisk, D-Wave, Lufthansa, Palantir, TUI, Microsoft, Bitcoin, Gold im Fokus
Top News
Tesla-Aktie ist Top-Pick der Deutschen Bank für 2026: Warum die Analysten optimistisch bleiben Tesla-Aktie ist Top-Pick der Deutschen Bank für 2026: Warum die Analysten optimistisch bleiben
finanzen.net ZERO XMAS-Aktion: Jetzt Neukundenbonus und bis zu 300 Euro Prämie sichern finanzen.net ZERO XMAS-Aktion: Jetzt Neukundenbonus und bis zu 300 Euro Prämie sichern
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

CSL Aktie

Kaufen
Verkaufen
CSL Aktien-Sparplan
98,55 EUR -1,25 EUR -1,25 %
STU
171,48 AUD -4,18 AUD -2,38 %
AUSX
CSL jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.47,44 Mrd. EUR

KGV25,01Div. Rendite1,89%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN890952

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINAU000000CSL8

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCMXHF

CSL Aktien News

DatumMeistgelesen
PR NewswireHealth Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
PR NewswireCSL Signs Renewable-Linked Power Purchase Agreement with AGL to Supply Electricity to Australian Manufacturing Sites
PR NewswireNew Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
PR NewswireCSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems
PR NewswireCSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources
PR NewswireCSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireFerinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
PR NewswireCSL Appoints Jeffrey Ball as First Chief Sustainability Officer
PR NewswireCSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season
PR NewswireCSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireInjectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireTopline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
PR NewswireCSL Seqirus Proud to Attend and Present at 2023 Canadian Immunization Conference
PR NewswireCSL Seqirus Proud to Attend and Present at 2023 Canadian Immunization Conference
PR NewswireCSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
PR NewswireCSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts
PR NewswireThe Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE
PR NewswireCSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

CSL News

CSL News: auf dieser Seite finden Sie alle CSL News und Nachrichten zur CSL Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CSL News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CSL News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.